Expert Interview
Discussing Abeona’s EB-101 recent Pivotal Phase 3 results in recessive dystrophic epidermolysis bullosa
Ticker(s): ABEOA geneticist with experience in treating recessive dystrophic epidermolysis bullosa, and knowledge of EB-101.
Please describe your clinical practice; how many patients with recessive dystrophic epidermolysis bullosa do you treat on a yearly basis, what percent of your patients could benefit from upcoming novel drugs? How much need is there for an autologous, engineered cell therapy such as EB-101?
Added By: slingshot_insightsCould you please share us your thoughts on the reported co-primary endpoint measuring >50% wound healing/ other endpoints measuring >75% and complete wound healing at six months? How much of a promise does it hold?
What are your thoughts regarding the pain reduction at six months data?
Since DEB is a rare connective tissue disorder without an approved therapy, how likely is the approval of EB-101, and it becoming standard of care?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
